McGill University has joined Moderna’s mRNA Access program, which aims to accelerate innovation and enable new vaccines and medicines for emerging and neglected infectious diseases through collaborative research and preclinical development. McGill is the first university in Canada to join this program as it ramps up its international rollout.
“This partnership is a sign of McGill’s strength in core research that changes lives,” said Martha Crago, Vice-Principal, Research & Innovation. “We are an acknowledged leader in mRNA, and joining this platform will help us develop vaccines that will protect human health everywhere on the planet.”
“Moderna’s goal is to create a global community of scientists who leverage our mRNA vaccine technology to develop innovative approaches to address emerging and neglected infectious diseases that pose a risk to public health,” said Hamilton Bennett BSc(FSc)’07, Senior Director of Vaccine Access and Partnerships, Moderna. “We look forward to working with McGill and our other global partners to prevent future pandemics and help millions of people around the world.”
The full article is available in the McGill Reporter.